[ad_1]
It is said to protect 92 percent of Covid-19. This was stated by the Russian state fund RDIF on Wednesday, based on the provisional results of the investigation. “We have a very effective vaccine,” said Kirill Dmitriev, director of the fund.
Back in August, Russia was the first in the world to register its Sputnik V coronavirus vaccine and received criticism from experts because it had been tested in humans for less than two months.
BioNTech and Pfizer announced Monday that their vaccine is more than 90 percent effective. This message caused euphoria in the world.
Russia has now presented the interim results of a major study launched in September. According to RDIF, the study is based on data from 16,000 participants who received two doses of the vaccine. An interim analysis was published when 20 participants became ill with Covid-19. These are significantly fewer than the 94 confirmed cases on which BioNTech and Pfizer interim results are based. To confirm the effectiveness of the vaccine, the study by both pharmaceutical companies will continue until a total of 164 cases of Covid-19 have been identified among 44,000 participants.
The Russian vaccine, developed by the Gamalea State Institute in Moscow, is being tested by 40,000 people. To date, no serious side effects have been identified with the RDIF data.
Russia released the Sputnik V vaccine to 10,000 high-risk people before the study began. President Vladimir Putin said he thought that mass vaccination of the population would begin by the end of the year.
Russia reported 432 more victims of the virus on Wednesday. This is the highest daily death toll since the pandemic began.
No part of this publication may be reproduced without the written permission of ELTA.
[ad_2]
